Alterity Therapeutics Limited, a development stage enterprise listed on both ASX (ATH) and NASDAQ (ATHE), has filed a Form 6-K with the Securities and Exchange Commission for the month of July 2024. The report, which serves as a notification of foreign private issuer, indicates that Alterity Therapeutics has complied with the necessary provisions of the Corporations Act 2001 (Cth) as they apply to the company. On July 18, 2024, Alterity issued 75,220,800 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has confirmed that as of the date of the notice, it has adhered to the requirements of Chapter 2M of the Corporations Act, as well as sections 674 and 674A. Furthermore, there is no 'excluded information' as defined in sections 708A(7) and 708A(8) of the Corporations Act that needs to be disclosed. This Form 6-K is also incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3.

Alterity Therapeutics Limited, a development stage enterprise listed on both ASX (ATH) and NASDAQ (ATHE), has filed a Form 6-K with the Securities and Exchange Commission for the month of July 2024. The report, which serves as a notification of foreign private issuer, indicates that Alterity Therapeutics has complied with the necessary provisions of the Corporations Act 2001 (Cth) as they apply to the company. On July 18, 2024, Alterity issued 75,220,800 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has confirmed that as of the date of the notice, it has adhered to the requirements of Chapter 2M of the Corporations Act, as well as sections 674 and 674A. Furthermore, there is no 'excluded information' as defined in sections 708A(7) and 708A(8) of the Corporations Act that needs to be disclosed. This Form 6-K is also incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3.